Amgen Inc. said over the weekend that it will pay Johnson & Johnson $200 million to settle litigation that alleged discounts offered by Amgen to cancer clinics violated antitrust laws.

In the 2005 lawsuit, J & J;’s Ortho Biotech unit alleged that Thousand Oaks-based Amgen violated antitrust laws when it gave discounts to oncology clinics that used its newer, longer-lasting anemia drug, Aranesp, which treats anemia associated with chemotherapy treatment, along with Neupogen and Neulasta, which helps prevent infections in chemotherapy patients.

Until Aranesp hit the market the two companies split the anemia market. Amgen’s Epogen was marketed for treatment of kidney disease patients, and Johnson & Johnson had the right to sell the same drug under the brand name Procrit as a treatment for cancer patients undergoing chemotherapy.

Ortho Biotech argued that Amgen was bundling sales of its anemia- and infection-fighting drugs in a way that forced cancer clinics to buy Aranesp, a successor to Epogen, rather than its drug.

Amgen said in a statement late Friday that its conduct was not unlawful and it admits to no wrongdoing.